StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH – Get Free Report) in a report issued on Saturday. The brokerage set a “sell” rating on the stock.
Bio-Path Stock Performance
Shares of NASDAQ BPTH opened at $0.95 on Friday. The company’s 50 day moving average price is $0.90 and its 200-day moving average price is $1.16. Bio-Path has a 52-week low of $0.59 and a 52-week high of $11.58.
Institutional Trading of Bio-Path
An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC bought a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path at the end of the most recent reporting period. 5.74% of the stock is owned by hedge funds and other institutional investors.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
See Also
- Five stocks we like better than Bio-Path
- Airline Stocks – Top Airline Stocks to Buy Now
- ServiceTitan Made Waves in Its IPO, But Is the Stock a Buy?
- How to Invest in Small Cap Stocks
- Netflix: Is This the Perfect Time to Buy a Streaming Powerhouse?
- What is the Hang Seng index?
- Goldman Sachs Unveils 3 Massive Opportunities for 2025 Investors
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
